Biotech stocks have had a rough post-pandemic. In a year where the S&P500 is up more than 10% year to date, the biotech sector is still negative to flat.
But biotech stocks will bounce back. Some biotech stocks will remain very volatile, especially small biotechs relying on clinical trials. However, the broader sector is still poised for consistent growth. As our population ages and healthcare becomes a larger share of our GDP, the biotech sector must grow to keep up with demand.
So for investors looking for safer biotech stocks, ones which can bring good returns but with lower volatility than the small caps, here are three bigwig biotech stocks to buy now.
This post originally appeared at InvestorPlace.